Protara Therapeutics Inc

TARA remains under Stage 4 decline pressure with a clear sequence of lower highs and lower lows, and price trading below the 9, 20, and 50 EMAs. Short-term pullback into the declining 9/20 EMA cluster presents an immediate sell opportunity. Key risks include a sustained reclaim of the 20 EMA accompanied by higher highs and lows, which would invalidate the bearish bias.

• ↑83% clinical success in STARBORN-1 trial; BLA filing due 2H 2027.
• ↑$161.9M cash reserves fund operations into 2028.
• ↓Q2 net loss of $21.7M ($0.36/sh) missed consensus.